Chugai Seiyaku Kabushiki Kaisha

Yuki Iwayanagi

Tomoyuki Igawa

Atsuhiko Maeda

Tatsuhiko Tachibana

Kenta Haraya

Hidetomo Kitamura

Yoshinobu Higuchi

Keiko Hirokawa

Ryosuke Mihara

Yumi Yamamoto

Tomohisa Saito

Hiroaki Matsushita

Akihisa Kaneko

Taichi Kuramochi

Shojiro Kadono

Hitoshi Katada

Futa Mimoto

Yuji Hori

Masaru Muraoka

Genki Nakamura

In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient

The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc&#x3b3; receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.

Method for altering plasma retention and immunogenicity of antigen-binding molecule

One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.

Methods of neutralizing IL-8 biological activity

Nucleic acids encoding IL-8 antibodies

Growing community of inventors

Shizuoka, Japan

Yuki Iwayanagi